Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double‐blind, placebo‐controlled, clinical trial-Reference-Cited by-同舟云学术

Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double‐blind, placebo‐controlled, clinical trial

Published:2021-09-18 Issue:11 Volume:75 Page:
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:Int J Clin Pract

Author:

Namkhah Zahra¹,Naeini Fatemeh¹,Mahdi Rezayat Seyed²,Mehdi Yaseri ³,Mansouri Siavash⁴,Javad Hosseinzadeh‐Attar Mohammad¹

Affiliation:

1. Department of Clinical Nutrition School of Nutritional Sciences and Dietetics Tehran University of Medical Science Tehran Iran

2. Department of Pharmacology School of Medicine Tehran University of Medical Sciences Tehran Iran

3. Department of Epidemiology and Biostatistics School of Public Health Tehran University of Medical Sciences Tehran Iran

4. National Iranian Oil Company (NIOC) Health and Family Research Center Tehran Iran

Funder

Tehran University of Medical Sciences and Health Services

Publisher

Hindawi Limited

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijcp.14852

Reference50 articles.

1. Non-alcoholic fatty liver disease: An expanded review

2. Nonalcoholic fatty liver disease - current status and future directions

3. Errors in meta-analysis on prevalence of nonalcoholic fatty liver disease

4. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future

5. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of Huatan Qushi Huoxue Fang granules on obese non-alcoholic fatty liver disease: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial;2024-09-04

2. Effects of different natural products in patients with non‐alcoholic fatty liver disease—A network meta‐analysis of randomized controlled trials;Phytotherapy Research;2024-06-17

3. Naringenin alleviates liver ﬁbrosis by triggering autophagy-dependent ferroptosis in hepatic stellate cells;Heliyon;2024-04

4. Natural compounds proposed for the management of non-alcoholic fatty liver disease;Natural Products and Bioprospecting;2024-04-01

5. Naringenin Orchestrates and Regulates the Reactive Oxygen Species-Mediated Pathways and Proinflammatory Signaling: Targeting Hallmarks of Aging-Associated Disorders;Rejuvenation Research;2024-02-01